cobas® vivoDx MRSA

Product image for COBAS®  VivoDx MRSA

Qualitative live-cell molecular test for methicillin-resistant Staphylococcus aureus (MRSA) - powered by innovative Smarticles technology

 

A new way to stay ahead of MRSA

 

The cobas® vivoDx MRSA provides rapid phenotypic detection of methicillin-resistant staphylococcus aureus (MRSA) colonization using the cobas® vivoDx System.  MRSA infections represent a tremendous burden on the healthcare system and are associated with significant healthcare costs.  As the first of a new class of molecular diagnostics based on the novel Smarticles technology, the cobas® vivoDx MRSA assay offers a new way to tackle MRSA in hospital infection prevention programs.

 

Explore a novel, high-performing and efficient method for MRSA screening

 

Innovative technology – Speed and simplicity of molecular diagnostics with phenotypic detection

Easy workflow – Direct from sample with <1 minute pre-analytical workflow per sample

Fast phenotypic result – ~5 hour turnaround time for timely infection control decisions

Confidence in results – direct detection, not limited by mechanisms of resistance

 

Through the combination of the innovative Smarticles technology and the automated cobas® vivoDx System, cobas® vivoDx MRSA offers an advanced option for MRSA detection.

 

Smarticles technology

 

Smarticles technology combines the speed and simplicity of molecular diagnostics with phenotypic detection to deliver rapid results. It requires minimal preparation and provides results in hours instead of days as compared to traditional growth-based identification and susceptibility test methods.

Learn more about Smarticles technology.

 

The cobas® vivoDx System
Product image for COBAS®  VivoDx MRSA

Powered by Smarticles technology, the cobas® vivoDx System provides an easy and flexible workflow that reduces contamination risk and the need to monitor on-board supply of reagents. With automated processing and connectivity, the system provides definitive answers for the direct detection multidrug-resistant organisms (MDROs).

 

Learn more about the cobas® vivoDx System.

 

MRSA

 

MRSA infections are one of the major causes of hospital-acquired infections and are associated with a huge healthcare burden.1 Learn more about MRSA through this infographic.

 

Performance (CE-IVD)

 

In clinical studies, cobas® vivoDx MRSA showed reliable and accurate performance.

Clinical Performance

Intended use

The cobas® vivoDx MRSA test performed on the cobas® vivoDx System is an automated qualitative in vitro diagnostic test for the direct detection of live methicillin-resistant Staphylococcus aureus (MRSA) cells in nasal swab samples from patients who are at risk for nasal colonization by MRSA. The test utilizes selective agents and Smarticles technology to create an amplified luminescent signal only in viable (live) MRSA cells. The cobas® vivoDx MRSA test is intended to aid in the prevention and control of MRSA infections in healthcare settings. It is not intended to diagnose, guide, or monitor treatment for MRSA infections. Concomitant cultures are necessary only to recover organisms for epidemiological typing or for further susceptibility testing.

Registration status

CE-IVD

Package inserts

Access package inserts through your country’s Roche Diagnostics website.

References